Capricor on Tuesday disclosed that the FDA has indicated that no AdCom is necessary for deramiocel’s Biologics License Application, and an in-person late-cycle review meeting is scheduled for mid-July, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. The firm, which has a Buy rating and $77 price target on the shares, highlights that even in bear case scenarios with the FDA, Phase 3 HOPE-3 data readouts are “waiting in the wings” to further strengthen deramiocel’s overall clinical and regulatory package and thinks deramiocel’s first-in-class therapeutic profile in tandem with strong manufacturing support will get the therapy over the finish line on expected timelines.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas" href="https://thefly.com/?utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">Try Now>>

>;elm:context_link;itc:0;sec:content-canvas" href="https://www.tipranks.com/screener/top-insider-trading-stocks/?type=stockAnalysisLanding&utm_source=finance.yahoo.com&utm_medium=referral" rel="nofollow noopener" target="_blank">See Insiders’ Hot Stocks on TipRanks >>

Read More on CAPR:

Disclaimer & DisclosureReport an Issue

• HHS spokesperson tells Reuters FDA ‘actively re-evaluating’ Capricor AdCom

• Capricor Therapeutics provides regulatory update on Deramiocel BLA

• Roth says ‘excessive’ Capricor selloff due to ‘investor overreaction’

• Capricor selloff brings buying opportunity, says H.C. Wainwright

• Capricor Therapeutics price target lowered to $22 from $43 at Oppenheimer